SCHIZOPHRENIA 1 (Disorder)NCT07144592
The Effects of a Solution-Focused Approach on Psychosocial Adjustment and Treatment Compliance in Individuals Diagnosed With Schizophrenia
A study testing solution-oriented approach program in people with SCHIZOPHRENIA 1 (Disorder) and Psychosocial Adaptation, run by Muş Alparslan University at 1 site in Turkey (Türkiye).
Trial summary
The aim of this study is to evaluate the effects of a solution-focused approach-based individual intervention on psychosocial adjustment and treatment adherence in individuals diagnosed with schizophrenia. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- SCHIZOPHRENIA 1 (Disorder), Psychosocial Adaptation, Treatment Adherence
- What is being tested?
- solution-oriented approach program
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Jan 2025to 25 Oct 2025
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Having been diagnosed with schizophrenia according to DSM-5 diagnostic criteria,
- Being between 18 and 65 years of age,
- Being literate and verbally communicative,
- Being clinically stable (not exhibiting symptoms of acute psychosis),
- Being registered with a Community Mental Health Center (CMHC) and receiving regular services,
- Being cognitively competent enough to participate in individual interviews during the research process,
- Being an individual currently receiving psychiatric treatment and taking medication,
- Agreeing to participate voluntarily in the study and signing a written informed consent form.
Who cannot join
- those who do not meet the inclusion criteria
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site, 1 recruiting
- Recruiting
Community Mental Health Center
Muş
muş alparsalan üniversity University, 0346 249 4949, sbf@alparslan.edu.tr
About this study
The aim of this study is to evaluate the effects of a solution-focused approach-based individual intervention on psychosocial adjustment and treatment adherence in individuals diagnosed with schizophrenia.
The study will be conducted as a randomized controlled trial including 60 clinically stable individuals diagnosed with schizophrenia according to DSM-5 criteria and registered at a Community Mental Health Center affiliated with a university hospital. Participants will be randomly assigned to an experimental group (n=30) and a control group (n=30).
The experimental group will receive one individual solution-focused therapy session per week for six weeks. The control group will receive usual care only. Data will be collected using a Personal Information Form, the Psychosocial Adjustment Scale (PSSAS), and the Medication Adherence Scale (MARS).
Read the detailed description
Objective:
Schizophrenia is a chronic psychiatric disorder that significantly affects thought, emotion, and behavior, often limiting social functioning, treatment adherence, and integration into daily life. There is an increasing need for person-centered, empowering, and brief intervention models in psychiatric nursing. This study aims to determine the effects of a solution-focused approach (SFA)-based individual intervention on psychosocial adjustment and treatment adherence in individuals with schizophrenia.
Study Design:
This research will use a pretest-posttest randomized controlled experimental design with a control group.
Study Population:
The study will include 60 individuals diagnosed with schizophrenia according to DSM-5 diagnostic criteria, considered clinically stable, and registered at a Community Mental Health Center affiliated with a university hospital in Türkiye. Participants will be randomly assigned to an experimental group (n=30) or a control group (n=30) using computer-assisted randomization.
Intervention:
Experimental Group: Participants will receive individual solution-focused therapy sessions once per week for six consecutive weeks. The sessions will emphasize individual strengths, recall positive coping experiences, support future goal setting, and provide guidance on repeating effective solutions.
Control Group: Participants will receive no additional intervention beyond usual care.
Outcome Measures:
Data will be collected with the following instruments:
Personal Information Form
Psychosocial Adjustment Scale (PSSAS)
Medication Adherence Scale (MARS)
Statistical Analyses:
Planned analyses will include independent samples t-tests, paired t-tests, and ANCOVA.
- Being tested
- solution-oriented approach program
- Keywords
- treatment adherence, Schizophrenia, solution-focused therapy,, psychiatric nursing
- Medical subject headings
- Treatment Adherence and Compliance, Schizophrenia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
solution-oriented approach programBehavioural
The solution-focused nursing intervention applied to the experimental group in the study was planned as individual sessions, consisting of one session per week, lasting a total of six weeks. The interventions were based on the principles of solution-focused brief therapy, focusing on the individual's strengths, past coping experiences, and current resources. The interviews aimed to identify exceptions, build positive future expectations, set small but achievable goals, strengthen hope, and increase the individual's ability to utilize their internal resources. Each session used structured open-ended questions, scaling techniques, and future-oriented solution scenarios to support the individual's psychosocial adjustment and motivation for treatment.
| Study group | Role | What they receive |
|---|---|---|
| experimental group (Solution-Focused Approach Program) | Experimental | A 6-week solution-focused approach program will be applied to the experimental group. Receives: Behavioral: solution-oriented approach program |
| control group (No Intervention: Usual Care at Community Mental Health Center) | No intervention | No intervention will be applied to the control group |
What is being measured
The primary outcome is the main question the study is designed to answer.
pretest (6-week solution-focused approach before the intervention)
- Psychosocial Adjustment (PSSAS)
Description: Measured with the Psychosocial Adjustment Scale (PSSAS), which assesses social relationships, daily life management, and coping with stress. Scores range from 0 to 180; higher scores indicate better psychosocial adjustment.
Time Frame: Baseline (within 1 week before intervention)
Unit of Measure: Total score (0-180)
Measured: Baseline (1 week before intervention)]
pretest (6-week solution-focused approach before the intervention)
- Medication Adherence (MARS)
Description: Measured with the Medication Adherence Scale (MARS), which assesses adherence to prescribed pharmacological treatment. Scores range from 0 to 10; higher scores indicate better medication adherence.
Time Frame: Baseline (within 1 week before intervention)
Unit of Measure: Total score (0-10)
Measured: Baseline (within 1 week before intervention)
Secondary outcomes (2)
posttest (After the 6-week solution-focused approach intervention)
- Psychosocial Adjustment Post-Intervention (PSSAS)
Description: Psychosocial Adjustment Scale (PSSAS). Scores range from 0 to 180; higher scores indicate better psychosocial adjustment.
Time Frame: 6 weeks after baseline (post-intervention)
Unit of Measure: Total score (0-180)
Measured: 6 weeks after baseline (post-intervention)
posttest (After the 6-week solution-focused approach intervention)
- Medication Adherence Post-Intervention (MARS)
Description: Medication Adherence Scale (MARS). Scores range from 0 to 10; higher scores indicate better medication adherence.
Time Frame: Post-intervention (6 weeks after completion of the intervention)
Unit of Measure: Total score (0-10)
Measured: Post-intervention (6 weeks after completion of the intervention)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Aug 2025
- Study start1 Jan 2025
- Primary completion25 Feb 2025
- Study completion25 Oct 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SCHIZOPHRENIA 1 (Disorder)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Muş Alparslan University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Fatih Sahin, Muş Alparslan University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07144592
- Sponsor's protocol ID
- 167678
- Status last verified
- Aug 2025
- First submitted
- 6 Aug 2025
- Last updated
- 27 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: will be shared at the end of the research
Study at a glance
From the registry record, last updated by the sponsor on 27 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effects of a Solution-Focused Approach on Psychosocial Adjustment and Treatment Compliance in Individuals Diagnosed With Schizophrenia
- ClinicalTrials.gov ID
- NCT07144592
- Acronym / sponsor ID
- 167678
- Keywords
- treatment adherence, Schizophrenia, solution-focused therapy,, psychiatric nursing
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Muş Alparslan UniversityUniversity, hospital or other
- Study start
- 1 Jan 2025 (actual)
- Primary completion
- 25 Feb 2025 (actual)
- Study completion
- 25 Oct 2025 (estimated)
- First posted
- 27 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to evaluate the effects of a solution-focused approach-based individual intervention on psychosocial adjustment and treatment adherence in individuals diagnosed with schizophrenia.
The study will be conducted as a randomized controlled trial including 60 clinically stable individuals diagnosed with schizophrenia according to DSM-5 criteria and registered at a Community Mental Health Center affiliated with a university hospital. Participants will be randomly assigned to an experimental group (n=30) and a control group (n=30).
The experimental group will receive one individual solution-focused therapy session per week for six weeks. The control group will receive usual care only. Data will be collected using a Personal Information Form, the Psychosocial Adjustment Scale (PSSAS), and the Medication Adherence Scale (MARS).
Detailed description
Objective:
Schizophrenia is a chronic psychiatric disorder that significantly affects thought, emotion, and behavior, often limiting social functioning, treatment adherence, and integration into daily life. There is an increasing need for person-centered, empowering, and brief intervention models in psychiatric nursing. This study aims to determine the effects of a solution-focused approach (SFA)-based individual intervention on psychosocial adjustment and treatment adherence in individuals with schizophrenia.
Study Design:
This research will use a pretest-posttest randomized controlled experimental design with a control group.
Study Population:
The study will include 60 individuals diagnosed with schizophrenia according to DSM-5 diagnostic criteria, considered clinically stable, and registered at a Community Mental Health Center affiliated with a university hospital in Türkiye. Participants will be randomly assigned to an experimental group (n=30) or a control group (n=30) using computer-assisted randomization.
Intervention:
Experimental Group: Participants will receive individual solution-focused therapy sessions once per week for six consecutive weeks. The sessions will emphasize individual strengths, recall positive coping experiences, support future goal setting, and provide guidance on repeating effective solutions.
Control Group: Participants will receive no additional intervention beyond usual care.
Outcome Measures:
Data will be collected with the following instruments:
Personal Information Form
Psychosocial Adjustment Scale (PSSAS)
Medication Adherence Scale (MARS)
Statistical Analyses:
Planned analyses will include independent samples t-tests, paired t-tests, and ANCOVA.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| experimental group (Solution-Focused Approach Program) | Experimental | Behavioral: solution-oriented approach programA 6-week solution-focused approach program will be applied to the experimental group. |
| control group (No Intervention: Usual Care at Community Mental Health Center) | No intervention | –No intervention will be applied to the control group |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Having been diagnosed with schizophrenia according to DSM-5 diagnostic criteria,
- Being between 18 and 65 years of age,
- Being literate and verbally communicative,
- Being clinically stable (not exhibiting symptoms of acute psychosis),
- Being registered with a Community Mental Health Center (CMHC) and receiving regular services,
Key exclusion criteria (1 listed)
- those who do not meet the inclusion criteria
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| solution-oriented approach programThe solution-focused nursing intervention applied to the experimental group in the study was planned as individual sessions, consisting of one session per week, lasting a total of six weeks. The interventions were based on the principles of solution-focused brief therapy, focusing on the individual's strengths, past coping experiences, and current resources. The interviews aimed to identify exceptions, build positive future expectations, set small but achievable goals, strengthen hope, and increase the individual's ability to utilize their internal resources. Each session used structured open-ended questions, scaling techniques, and future-oriented solution scenarios to support the individual's psychosocial adjustment and motivation for treatment. | Behavioural | experimental group (Solution-Focused Approach Program) |
Primary outcome
pretest (6-week solution-focused approach before the intervention)
Time frame: Baseline (1 week before intervention)]
1. Psychosocial Adjustment (PSSAS) Description: Measured with the Psychosocial Adjustment Scale (PSSAS), which assesses social relationships, daily life management, and coping with stress. Scores range from 0 to 180; higher scores indicate better psychosocial adjustment. Time Frame: Baseline (within 1 week before intervention) Unit of Measure: Total score (0-180)
pretest (6-week solution-focused approach before the intervention)
Time frame: Baseline (within 1 week before intervention)
2. Medication Adherence (MARS) Description: Measured with the Medication Adherence Scale (MARS), which assesses adherence to prescribed pharmacological treatment. Scores range from 0 to 10; higher scores indicate better medication adherence. Time Frame: Baseline (within 1 week before intervention) Unit of Measure: Total score (0-10)
2 secondary outcomes
posttest (After the 6-week solution-focused approach intervention)
Time frame: 6 weeks after baseline (post-intervention)
posttest (After the 6-week solution-focused approach intervention)
Time frame: Post-intervention (6 weeks after completion of the intervention)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Aug 2025.
- Individual participant dataSharing planned: No. will be shared at the end of the research
Related trials for SCHIZOPHRENIA 1 (Disorder)
Recruiting
MI-CBTech: A Mobile Intervention for Community Integration in Homeless-Experienced Veterans With SMI
Schizophrenia Spectrum Disorders, Psychotic Affective Disorders
RecruitingObservational study
Tau Biomarkers in Late-onset Psychosis (LOP)
Late Onset Schizophrenia, Delusional Disorder (Late Onset)
Active, not recruitingObservational study
Profiling Vulnerability and Resilience for Mental Illness Following Viral Infections
Severe Mental Illness, Inflammation
Recruiting
REACH Study (Recovery Environments: Assessing Cognitive & Brain Health in Community Mental Health)
Schizophrenia, Schizo Affective Disorder
RecruitingPhase 3
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
Schizophrenia, Bipolar Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing solution-oriented approach program in people with SCHIZOPHRENIA 1 (Disorder) and Psychosocial Adaptation, run by Muş Alparslan University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 27 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Fatih Şahin, dr (0534 688 1634, fatih.sahin@alparslan.edu.tr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
pretest (6-week solution-focused approach before the intervention) (time frame: Baseline (1 week before intervention)]). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Aug 2025; AzTrials last refreshed its copy on 6 Nov 2026.